| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-08-08 | Fate Therapeutics (USA - CA) | $10.3 million | private placement | Cancer - Oncology - Immunological diseases | Private placement | |
| 2016-08-02 | Avrobio (USA - MA) | $25 million | series A financing round | Atlas Venture (USA) Clarus (USA) SV Life Sciences (USA) | Cancer - Oncology - Rare diseases - Genetic diseases | Series A financing round |
| 2016-07-31 | InflaRX (Germany), international industrial investors, family offices, existing investors. | € 31 million ($ 34 million) | series C financing round | Staidson Hongkong Investment Company (China) | Inflammatory diseases | Series C financing round |
| 2016-07-29 | Biophytis (France) | € 1.1 million | loan | Bpifrance (France) | Muscle disorders | Loan |
| 2016-07-28 | Nicox (France) | €18 million | capital increase | Ophtalmological diseases | Capital increase | |
| 2016-07-19 | Precision Ocular (UK) | £15.5 million | series A financing round | Imperial Innovations (UK) Consort Medical (UK) NeoMed (Switzerland) V?Bio Ventures (Belgium) Hovione Scientia (Portugal) | Ophtalmological diseases | Series A financing round |
| 2016-07-19 | Auris Medical (Switzerland) | up to $ 20 million | loan | Hercules Capital (USA - CA) | Otorhinolaryngology | Loan |
| 2016-07-18 | Poxel (France) | €26.5 million | capital increase | institutional investors in the United States and in Europe. | Metabolic diseases | Capital increase |
| 2016-07-13 | Galena Biopharma (USA - OR) | $11.7 million | private placement | Cancer - Oncology | Private placement | |
| 2016-07-08 | Horama (France) | fundraising | € 4 million | Bpifrance (France) and private investors (shareholders and Vendée entrepreneurs) Omnes Capital (France) Go Capital (France) Sham Innovation (France) | Ophtalmological diseases | Series A financing round |
| 2016-06-30 | Bionor Pharma (Norway) | private placement | Infectious diseases | Private placement | ||
| 2016-06-29 | Paion (Germany) | € 9.6 million | capital increase | Cosmo Pharmaceuticals (Ireland) Granell Strategic Investment Fund (ireland) | CNS diseases | Capital increase |
| 2016-06-27 | Emergent Biosolutions (USA - MD) | up to $21.9 million | grant | Biomedical Advanced Research and Development Authority (BARDA) (USA) | Infectious diseases | Grant |
| 2016-06-24 | Global Blood Therapeutics (USA - CA) | $112.3 million | private placement | Rare diseases - Genetic diseases - Hematological diseases | Private placement | |
| 2016-06-22 | Neovacs (France) | € 8.7 million | capital increase | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Capital increase | |
| 2016-06-20 | F2G (UK) | $60 million (€ 52.8 milion) | financing round | Sectoral Asset Management (Canada) Novo A/S (Denmark) Aisling Capital (USA - NY) Brace Pharma Capital (USA - MD) Advent Life Sciences (UK) Novartis Venture Fund (Switzerland) Sunstone Capital (Denmark) Merifin Capital (UK) | Infectious diseases | Financing round |
| 2016-06-20 | Spark Therapeutics (USA - PA) | $128.0 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2016-06-15 | Allecra Therapeutics (Germany - France) | €22 million | series B financing round | Delos Capital (USA - NY) Forbion Capital Partners (The Netherlands) Edmond de Rothschild Investment Partners (France) EMBL Ventures (Germany) Nicholas Benedict | Infectious diseases | Series B financing round |
| 2016-06-15 | Corbus Pharmaceuticals (USA - MA) | $15 million | private placement | Fibrotic diseases - Inflammatory diseases | Private placement | |
| 2016-06-09 | Mereo BioPharma (UK) | £14.8 million | IPO | Rare diseases | IPO |
